Beyond A1C: Can CGM Help Prevent Severe Hypoglycemia and DKA?

Continuous glucose monitoring has changed how clinicians and people with diabetes think about glucose control. Yet the next question is more important than whether CGM improves A1C or Time in Range. Can it prevent events that send patients to the emergency department or hospital? Growing evidence suggests that CGM may help with severe hypoglycemia prevention beyond simply providing early warnings, while CGM use may also help reduce diabetic ketoacidosis (DKA) risk. However, the distinction between predicting risk and actually preventing an event remains important.

Table of Contents

• Beyond A1C: What CGM Data Can Reveal About Acute Risk
• Can CGM Help Prevent Severe Hypoglycemia?
• Can CGM Also Reduce Diabetic Ketoacidosis?
• Turning CGM Risk Detection Into Prevention
• Conclusion
• Frequently Asked Questions

Beyond A1C: What CGM Data Can Reveal About Acute Risk

A1C remains a valuable measure of average glycemia, but averages can hide dangerous glucose patterns. Two patients with the same A1C may experience very different levels of hypoglycemia, glucose variability, and prolonged hyperglycemia. Therefore, CGM metrics can add clinically useful information that A1C alone cannot provide.

The American Diabetes Association’s 2026 Standards of Care recommend CGM for people at high risk for hypoglycemia. The ADA also notes that Time Below Range (TBR), Time Above Range (TAR), and glucose variability can guide treatment changes and help with real-time detection and prevention of hypoglycemia.

Importantly, severe hypoglycemia is not simply a very low sensor reading. Level 3 hypoglycemia is defined by altered physical or mental functioning that requires another person’s assistance, regardless of the measured glucose level. Consequently, studies focused only on minutes spent below 70 mg/dL cannot fully answer whether CGM prevents severe clinical events.

Recent research is beginning to address that gap. A 2026 pooled analysis in Diabetes Care examined CGM data from 1,550 people with type 1 diabetes across 10 studies. During a median 16-week follow-up, researchers recorded 65 severe hypoglycemia events and 163 DKA events. The study specifically evaluated whether CGM-derived patterns could identify future risk beyond HbA1c.

That shift matters. Instead of asking only, “Did A1C improve?” researchers can increasingly ask, “What does this patient’s glucose pattern tell us about the chance of a dangerous event?”

Can CGM Help Prevent Severe Hypoglycemia? What the Evidence Shows

The strongest evidence that CGM may help prevent severe hypoglycemia begins with its ability to reveal glucose patterns that finger-stick testing may miss. Real-time alerts can warn patients when glucose is low or falling rapidly. In addition, retrospective CGM reports can reveal recurrent overnight lows or periods of high variability that deserve treatment changes.

Population data support a relationship between these patterns and severe events. A large European study included 32,117 children, adolescents, and young adults with type 1 diabetes. Severe hypoglycemia occurred at a rate of 6.74 events per 100 patient-years among CGM users versus 8.84 among blood glucose monitoring users. That represented an adjusted incidence rate ratio of 0.76.

Moreover, risk rose as Time Below Range increased. Participants spending at least 8% of their time below 70 mg/dL had more than twice the severe hypoglycemia rate of those spending less than 4% below range. A coefficient of variation of 36% or greater was also associated with higher severe hypoglycemia rates.

A 2025 study of youth with type 1 diabetes found a similar signal. Participants with less than 45% Time in Range had about twice the rate of severe hypoglycemia compared with those at or above 45%. Likewise, a glucose coefficient of variation of at least 41% was associated with roughly twice the event rate.

These findings suggest CGM may function like an early-warning radar. However, seeing the storm does not automatically prevent it. Prevention still requires patients, caregivers, clinicians, or automated insulin delivery systems to respond appropriately.

Can CGM Also Reduce Diabetic Ketoacidosis?

DKA presents a different challenge. Low-glucose alerts can prompt an immediate response, whereas DKA develops through insulin deficiency, hyperglycemia, ketone production, dehydration, and other factors. Still, CGM may provide valuable warning signs before the situation becomes critical.

In the European population study, DKA occurred at 3.72 events per 100 patient-years among CGM users compared with 7.29 among people using blood glucose monitoring. In addition, DKA risk climbed sharply with higher mean sensor glucose.

Adult data are increasingly supportive as well. A 2025 study involving 13,616 adults with type 1 diabetes in Spain examined DKA hospitalizations before and after adoption of intermittently scanned CGM. DKA admissions fell from 79.26 to 40.28 per 10,000 person-years. Notably, the largest reduction occurred among people with an A1C of 10% or higher.

Meanwhile, a nationwide 2026 Korean cohort adds another important piece of evidence. Researchers compared 8,509 CGM users with 8,509 matched non-users. CGM use was associated with a substantially lower adjusted risk of DKA. Furthermore, among CGM users, DKA-related hospital or emergency visits decreased by 60% after CGM initiation.

Severe hypoglycemia results were more nuanced. Adjusted rates did not differ significantly between CGM users and non-users overall. However, severe hypoglycemia events among CGM users decreased by 61.5% after CGM initiation. Researchers noted that people already at high risk for severe hypoglycemia may be particularly likely to adopt CGM, which can complicate comparisons between users and non-users.

Therefore, observational findings should not be interpreted as proof that CGM alone prevents DKA or severe hypoglycemia. Access to specialty care, education, treatment engagement, insulin delivery methods, and socioeconomic factors may also influence outcomes.

Turning CGM Risk Detection Into Prevention

For clinicians, using CGM to prevent severe hypoglycemia involves more than checking whether a patient wears a sensor. The greater value may come from identifying actionable patterns and responding before those patterns become emergencies.

Time Below Range deserves particular attention in patients with recurrent hypoglycemia. Similarly, high glucose variability may identify someone whose A1C looks acceptable while masking repeated excursions. The ADA recommends a TBR below 70 mg/dL of less than 4% for most adults and a TBR below 54 mg/dL of less than 1%.

For DKA risk, persistent severe hyperglycemia, rising mean sensor glucose, and prolonged Time Above Range should trigger closer evaluation. However, CGM measures glucose, not ketones. Therefore, suspected DKA still requires appropriate ketone testing and clinical assessment, particularly during illness or when insulin delivery may have been interrupted.

Patients with previous severe hypoglycemia deserve special attention because prior level 2 or level 3 events are among the strongest predictors of recurrence. People with impaired hypoglycemia awareness, high glycemic variability, recurrent nocturnal lows, or intensive insulin therapy may also gain substantial safety value from real-time alerts.

Likewise, people with repeated DKA, very high A1C, frequent sustained hyperglycemia, or difficulty recognizing deteriorating glucose control may benefit from CGM-supported intervention. Still, technology works best when paired with education, reliable sensor use, an individualized treatment plan, and clear instructions about when to check ketones or seek urgent medical care.

For additional clinical information and diabetes management resources, readers can explore Diabetes in Control. Patients who need personalized medical guidance should speak with their diabetes care team or a qualified healthcare professional.

Conclusion

The evidence that CGM may reduce the risk of severe hypoglycemia is becoming stronger, but the story goes beyond a single metric. CGM can reveal Time Below Range, glucose variability, sustained hyperglycemia, and other patterns that A1C may conceal. Large observational studies also associate CGM use with fewer severe hypoglycemia events and substantially lower DKA rates in several populations.

However, risk prediction and prevention are not identical. Much of the evidence for severe clinical outcomes remains observational, and confounding cannot be completely excluded. CGM should therefore be viewed as part of a broader safety system that includes education, appropriate insulin management, ketone testing when indicated, and rapid responses to dangerous glucose trends.

The key clinical question is no longer simply whether CGM improves A1C. Increasingly, it is whether clinicians can use CGM data to identify risk early enough to prevent the next emergency.

Frequently Asked Questions

Can CGM prevent severe hypoglycemia?

CGM can reduce hypoglycemia and provide alerts before glucose reaches dangerous levels. Observational evidence also links CGM use with fewer severe events. However, successful prevention depends on appropriate responses to alerts and treatment adjustments.

Which CGM metric may signal severe hypoglycemia risk?

Time Below Range and glucose variability are particularly useful. Research has associated greater time below 70 mg/dL and higher coefficients of variation with increased severe hypoglycemia risk.

Can CGM prevent diabetic ketoacidosis?

CGM cannot directly diagnose or treat DKA. However, it can identify sustained or worsening hyperglycemia, allowing earlier action. Large observational studies have associated CGM use with lower DKA rates and fewer DKA hospitalizations.

Does a good A1C mean a patient has low hypoglycemia risk?

Not necessarily. A1C represents average glucose and can hide frequent highs and lows. CGM adds information about Time Below Range, Time Above Range, Time in Range, and glucose variability.

Who may benefit most from CGM for preventing acute complications?

People using insulin who have recurrent hypoglycemia, impaired hypoglycemia awareness, high glucose variability, previous severe hypoglycemia, sustained hyperglycemia, or previous DKA may particularly benefit from CGM-supported risk management.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.